<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine the role of colonic barrier defects and low-grade <z:mp ids='MP_0001845'>inflammation</z:mp> in <z:e sem="disease" ids="C0022104" disease_type="Disease or Syndrome" abbrv="IBS">irritable bowel syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>)-like symptoms in quiescent <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Caecal biopsies were collected from 51 IBS, 49 quiescent IBD (31 <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD) and 18 <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC)) patients and 27 controls </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> was assessed using the Rome III criteria and the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> severity score </plain></SENT>
<SENT sid="3" pm="."><plain>Epithelial barrier integrity was evaluated by determining the paracellular permeability of biopsies mounted in Ussing chambers and the <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of tight junction proteins (ZO-1, α-catenin and occludin) </plain></SENT>
<SENT sid="4" pm="."><plain>Low-grade <z:mp ids='MP_0001845'>inflammation</z:mp> was evaluated by counting cells, including intraepithelial lymphocytes (IELs), eosinophils and mast cells, and by determining the <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-α in biopsies and culture supernatants </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>-like symptoms were present in 35.4 and 38% of CD and UC patients, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Paracellular permeability was significantly increased in both quiescent IBD with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>-like symptoms and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> compared with quiescent IBD without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>-like symptoms (p&lt;0.01, respectively) or controls (p&lt;0.01, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Significantly lower expression of ZO-1 and α-catenin was detected in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> and quiescent IBD with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>-like symptoms </plain></SENT>
<SENT sid="8" pm="."><plain>IELs and TNF-α were significantly increased in quiescent IBD with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>-like symptoms, but not in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In quiescent IBD, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>-like symptoms related to persistent subclinical <z:mp ids='MP_0001845'>inflammation</z:mp> associated with increased colonic paracellular permeability </plain></SENT>
<SENT sid="10" pm="."><plain>A persistent increase in TNF-α in colonic mucosa may contribute to the epithelial barrier defects associated with <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> in quiescent IBD, but not in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Optimisation of anti-inflammatory therapy may be considered in quiescent IBD with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>-like symptoms </plain></SENT>
</text></document>